Concepedia

May S.K. Sutherland

MS

11

Publications

1K

Citations

10

H-Index

1994

Active since

Affiliations

Seagen (United States)(Current)

St. Michael's Hospital

Fred Hutch Cancer Center

University of Toronto

May S.K. Sutherland is an author at Seagen (United States) specializing in medicine, bone metabolism, and orthopaedics.

Top concepts

Publications per year

1994–2015

11

Publications

11

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey et al. · Blood · 2013 · 381 citations

Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates

May S.K. Sutherland, Russell J. Sanderson, Kristine A. Gordon et al. · Journal of Biological Chemistry · 2006 · 291 citations · Full text

Sclerostin Inhibition of Wnt-3a-induced C3H10T1/2 Cell Differentiation Is Indirect and Mediated by Bone Morphogenetic Proteins

David G. Winkler, May S.K. Sutherland, Ethan W. Ojala et al. · Journal of Biological Chemistry · 2004 · 164 citations · Full text

IL-6 as a drug discovery target

Bernd Stein, May S.K. Sutherland · Drug Discovery Today · 1998 · 44 citations

, , +5

Age-dependent expression of osteoblastic phenotypic markers in normal human osteoblasts cultured long term in the presence of dexamethasone

May S.K. Sutherland, L.G. Rao, Syed A. Muzaffar et al. · Osteoporosis International · 1995 · 37 citations

, , +10

Rows per page

1–5 of 11